Clinical Trials Logo

Novel Coronavirus Pneumonia clinical trials

View clinical trials related to Novel Coronavirus Pneumonia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05305456 Completed - Clinical trials for Novel Coronavirus Pneumonia

Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19

Start date: March 28, 2022
Phase: Phase 3
Study type: Interventional

This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.

NCT ID: NCT04645407 Completed - Clinical trials for Novel Coronavirus Pneumonia

Effects of Fuzheng Huayu Tablets on COVID-19

Start date: February 1, 2020
Phase: Phase 4
Study type: Interventional

The 2019 novel coronavirus (2019-nCoV) infection caused clusters of severe respiratory illness similar to SARS and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected 2019-nCoV, most of them should receive supportive care to help relieve symptoms. This clinical trial is to evaluate the effect of Fuzheng Huayu tablet on lung inflammation in intensive patients with novel coronavirus pneumonia and reduce the progressive rate to critical type.

NCT ID: NCT04280224 Completed - Clinical trials for Novel Coronavirus Pneumonia

NK Cells Treatment for COVID-19

Start date: February 15, 2020
Phase: Phase 1
Study type: Interventional

Since december 2019, acute respiratory disease due to 2019 novel coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. There is no confirmed antivirus therapy for 2019-nCoV infection. Natural killer (NK) cells are innate lymphocytes that may serve as useful effectors against danger infection. The purpose of this clinical investigation is to evaluate the safety and efficiency of NK Cells in combination with standard therapy for pneumonia patients infected with 2019-nCoV.

NCT ID: NCT04273321 Completed - COVID-19 Clinical Trials

Efficacy and Safety of Corticosteroids in COVID-19

Start date: February 14, 2020
Phase: N/A
Study type: Interventional

There is still controversy about the effective of glucocorticoids for the treatment of novel coronavirus pneumonia. This is a prospective randomized controlled trails. The aim is to explore the effectiveness and safety of glucocorticoids in the treatment of novel coronavirus pneumonia.